Billionaires may well have enabled our greatest (only?) policy successes in 2020.
"Economists are accustomed to thinking about tradeoffs," says economist and Nobel laureate Alvin Roth. "It appears that at least in some parts of the ethics community, they are not."
The Trump Administration's $765 Million Kodak Deal Is More Proof That 'Economic Nationalism' Is a Scam
The Trump administration's "economic nationalist" agenda is little more than a cronyist attempt at propping up domestic companies with taxpayer cash.
The Food and Drug Administration now says there is no evidence that any country attempted to cut off America's essential pharmaceuticals.
The Trump Administration Wants To Subsidize Domestic Drug Manufacturing. The First Contract Looks Like a $350 Million Grift.
A member of the five-month-old company's board has been touting bogus stats about America's supposed dependency on Chinese-made drugs.
Stocks rise steeply on good news about mRNA vaccines.
None have yet emerged that can clearly stem the tide of the ongoing pandemic.
The science is unsettled, and a new warning label would probably just confuse people.
The Right to Try movement, which recently became federal law, allows doctors to prescribe experimental treatments that haven't been approved for sale by regulators.
When and wherever public health conflicted with personal freedom, Gottlieb advocated for the former.
Plus: Tumblr porn filters catch company's own examples of permitted content and how the GOP learned to love bailouts.
"Our vision for a new, more transparent drug-pricing system does not rely on voluntary action," says HHS Secretary Alex Azar.
Plus: Parkour robots, price transparency for drugs, and Hillary Clinton defending Bill over the Lewinsky affair
Initiatives to curb drug-maker influence have endangered medical workers, patients, and the healthcare system.
Expect Fully Legal Weed Within 5 Years, Says Former Top Pharma Lobbyist and Congressman Billy Tauzin
He has been a Democrat, a Republican, a lobbyist, and a cancer survivor. Now he wants to end the war on weed.
It's still not clear whether pharmaceutical companies will work with patients outside the FDA's supervision.
From ripping families apart to nominating a torture-enabler as CIA director, the administration is calling the GOP's bluff, Reason editors argue.
Change drug prices by changing the market.
Making drug-company shareholders foot the bill for a public health crisis is flaky and counterproductive.
The drug regulator's clinical trials process for approving drugs needs a complete overhaul.
The change would put D.C. in line with a rapidly rising number of states allowing pharmacist-prescribed oral contraceptives.
Do the pain relief benefits of prescription opioids outweigh their addiction risks?
What will really keep drug (and any other) prices lower? Competition.
Reason editors talk immigration, affirmative action, and why the "Pharma Bro" witch hunt should concern everyone.
Senate approves bill giving some earlier access to treatment.
The pharmaceutical market is anything but free at present.
Make pharmaceutical competition great again.
Contrary to what The New York Times claims, the outcry over EpiPen prices has made them lower.
Understands how over-regulation is slowing down innovation in medicines and foods
Americans would save some money now, but at the long-run cost of sicker and shorter lives
The unintended consequences to Americans' lives and health would be substantial and bad
Slashing the restraints on the agency's slow and burdensome process.
A Reason investigation uncovers how cops, prosecutors, and lobbyists conspired to restrict a promising cannabis-derived seizure treatment.
At Planned Parenthood clinics, 43 percent of all abortions are now drug-induced, not surgical.
As if fentanyl's public relations aren't bad enough.
"Right to try" laws offer hope for people trying to save their own lives.
The freedom to set prices free of government coercion makes for better newspapers and better medicine.
Hillary Clinton's Plan to Control Drug Prices Is Symptomatic of a Failed National Health Care Policy
The vast reach of government as a payer for health care means that drug companies are to a large degree government contractors, and patients are suffering.